Neuroendocrine Tumors of Old Patients in the West of France

Neuroendocrine Tumors Clinical Trial

— TANGO  

Official title:

Neuroendocrine Tumors of Patients Aged of 75 y or Over in the West of France

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03749681
• Other study ID #: TANGO (29BRC18.0013)
• Status: Not yet recruiting
• Start date: December 2018
• Est. completion date: March 28, 2020

Study information

• Verified date: March 2018
• Source: University Hospital, Brest
• Contact: Jean-Philippe METGES
• Phone: 02-98-22-33-62
• Email: jean-philippe.metges[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan.

The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 306
• Est. completion date: March 28, 2020
• Est. primary completion date: March 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• 75 years old or over at the time of diagnosis

• Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis

• Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017

• Patient with care in private and public centers in the West of France

Exclusion Criteria:

• Patient with cancer other than a neuroendocrine tumor

• Patient with a G4 neuroendocrine tumor

• Patient who has objected to the study and collection of his medical data

• Refusal of participation

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Brest	Novartis

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report	statistical analysis (%)	03/31/2020
Primary	All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3)	statistical analysis (%)	03/31/2020
Primary	Histology, differentiation status	qualitative description (text)	03/31/2020
Primary	mitotic index and proliferation idex of the tumor	statistical analysis (%)	03/31/2020
Primary	Response rate	statistical analysis (%)	03/31/2020
Primary	progression free survival	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file	03/31/2020
Primary	overall survival	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file	03/31/2020